Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 7/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TTR | P02766 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3179944 | 1.00 | ABL1 (0.51) | ABL1MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL3167942 | 0.88 | MAPT (0.49) | ABL1MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL3167924 | 0.88 | MAPT (0.49) | ABL1MAPTALDH1A1MEN1KMT2A | |
| Methyl 3-(2,4-Dichlorophenyl)Acrylate SCHEMBL7434845 | 0.84 | MAPT (0.62) | MAPTALDH1A1MEN1KMT2AKDM4E | |
| Methyl 3-(2,4-Dichlorophenyl)Acrylate SCHEMBL6315070 | 0.84 | MAPT (0.62) | MAPTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL6171573 | 0.84 | MAPT (0.48) | ABL1MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL6171567 | 0.84 | MAPT (0.48) | ABL1MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL6171196 | 0.83 | ALDH1A1 (0.50) | MAPTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL6171189 | 0.83 | ALDH1A1 (0.50) | MAPTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL31155851 | 0.83 | MAPT (0.58) | MAPTALDH1A1MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645760-B2 | 1-(4-Benzyl-piperazin-1-yl)-3-phenyl-propenone derivatives | NOVARTIS AG. (CH) | 2010-01-12 | — | — | US | disclosed |
| US-7645760-B2 | 1-(4-Benzyl-piperazin-1-yl)-3-phenyl-propenone derivatives | NOVARTIS AG. (CH) | 2010-01-12 | — | — | US | disclosed |
| US-7645760-B2 | 1-(4-Benzyl-piperazin-1-yl)-3-phenyl-propenone derivatives | NOVARTIS AG. (CH) | 2010-01-12 | — | — | US | disclosed |
| US-20070196270-A1 | Compounds As Ccri Antagonists | HENG RICHARD | 2007-08-23 | — | — | US | disclosed |
| US-20070196270-A1 | Compounds As Ccri Antagonists | HENG RICHARD | 2007-08-23 | — | — | US | disclosed |
| US-20070196270-A1 | Compounds As Ccri Antagonists | HENG RICHARD | 2007-08-23 | — | — | US | disclosed |
| EP-1794164-A2 | BRIDGED PIPERAZINE AND PIPERIDINE DERIVATIVES AS CCR1 ANTAGONISTS | Novartis AG (CH) | 2007-06-13 | — | — | EP | disclosed |
| US-20060173004-A1 | 1-(4-Benzyl-piperazin-1-yl)-3-phenyl-propenone derivatives | NOVARTIS AG (CH) | 2006-08-03 | — | — | US | disclosed |
| WO-2005103054-A2 | BRIDGED PIPERAZINE AND PIPERIDINE DERIVATIVES AS CCRI ANTAGONISTS | NOVARTIS AG (CH) | 2005-11-03 | — | — | WO | disclosed |
| EP-1045833-B1 | 2,3-SUBSTITUTED INDOLE COMPOUNDS AS COX-2 INHIBITORS | PFIZER (US) | 2005-11-02 | — | — | EP | disclosed |
| US-6608070-B1 | Useful for treatment of medical condition in which prostaglandins are implicated as pathogens | NAKAO KAZUNARI (JP) | 2003-08-19 | — | — | US | disclosed |
| EP-1065206-B1 | Tetrazolylalkyl indole compounds as anti-inflammatory and analgesic agents | PFIZER (US) | 2002-10-09 | — | — | EP | disclosed |
| EP-1065204-B1 | Bicycliccarbonyl indole compounds as anti-inflammatory/analgesic agents and as COX-2 inhibitors | PFIZER (US) | 2002-04-10 | — | — | EP | disclosed |
| US-6303628-B1 | FOR THE TREATMENT OF A MEDICAL CONDITION IN WHICH PROSTAGLANDINS ARE IMPLICATED AS PATHOGENS IN MAMMALS | PFIZER INC | 2001-10-16 | — | — | US | disclosed |
| CN-1284064-A | 2,3-substituted indole compounds as cox-2 inhibitors | PFIZER PHARMA (US) | 2001-02-14 | — | — | CN | disclosed |
| EP-1065204-A1 | Bicycliccarbonyl indole compounds as anti-inflammatory/analgesic agents and as COX-2 inhibitors | PFIZER INC. (US) | 2001-01-03 | — | — | EP | disclosed |
| EP-1065206-A1 | Tetrazolylalkyl indole compounds as anti-inflammatory and analgesic agents | PFIZER INC. (US) | 2001-01-03 | — | — | EP | disclosed |
| US-5376748-A | Antiepileptic agents, anticonvulsants | MERCK SHARP & DOHME LIMITED (GB) | 1994-12-27 | — | — | US | disclosed |
| EP-0623111-A1 | NITROQUINOLONE DERIVATIVES AS NMDA ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 1994-11-09 | — | — | EP | disclosed |
| WO-1993014067-A1 | NITROQUINOLONE DERIVATIVES AS NMDA ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 1993-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173004-A1 | 1-(4-Benzyl-piperazin-1-yl)-3-phenyl-propenone derivatives | CCR1, CCR3, CCR4 | ABL1 2775/4885MAPT 2279/4885ALDH1A1 290/4885 |
| US-20070196270-A1 | Compounds As Ccri Antagonists | CCR1, CCR10, CCR4 | ABL1 2299/4885MAPT 2220/4885ALDH1A1 743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.